drugset / Trial / NCT07526870

Intradermal Microbotulinum Toxin for Sebum Reduction and Facial Pore Improvement

NCT07526870

NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of microdoses of botulinum toxin type A (microtoxin) for improving periocular skin quality and reducing fine wrinkles. Botulinum toxin is commonly used in aesthetic medicine; however, its use in microdoses has been proposed to achieve more natural results with fewer adverse effects. Participants with periocular rhytids will receive intradermal injections of diluted botulinum toxin. Clinical outcomes will include improvement in skin texture, wrinkle reduction, and patient satisfaction. Safety will be assessed by monitoring adverse events. The findings of this study may help determine whether microtoxin is an effective and safe option for minimally invasive periocular rejuvenation.

Timeline

Start
2024-07-24
Primary completion
2024-11-24
Completion
2024-11-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic Other

Indications

No indication recorded.